EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Efficacy and Safety of Elobixibat in Parkinson's Disease with Chronic Constipation: CONST‐PD Study

Taku Hatano iD, Genko Oyama iD, Yasushi Shimo, Kotaro Ogaki, Noriko Nishikawa iD, Ryota Nakamura, Taiji Tsunemi iD, Takashi Ogawa iD, Hiroto Eguchi, Kensuke Daida iD, Naohide Kurita, Shin-Ichi Ueno und 19 weitere

Movement Disorders Clinical Practice · 2024

DOI: 10.1002/mdc3.13972 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Movement Disorders Clinical Practice, 2024. Verfasst von Taku Hatano und 30 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Juntendo University Faculty of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Dipeptides, Gastrointestinal Diseases, Parkinson Disease, Thiazepines. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mochida Pharmaceutical Co., Ltd., EA Pharma Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chronic constipation is a common digestive complication of Parkinson's disease (PD).

Objectives

To verify the usefulness of elobixibat, an ileal bile acid transporter inhibitor, for chronic constipation in PD.

Methods

This double‐blind, placebo‐controlled study consisted of a 2‐week observation/washout period and a 4‐week treatment period. All patients received a Bowel Movement Diary at Week ‐2 and were allocated to elobixibat (10 mg) or placebo at Week 0. Patients visited at Weeks 2 and 4 to report daily spontaneous bowel movements (SBM), stool form, drug use, quality of life (QOL), and safety. Changes in these parameters were assessed.

Results

The study included 38 patients in the elobixibat group and 39 in the placebo group, and 37 each completed the study. SBM frequency/week (mean ± standard deviation) increased significantly from 4.2 ± 2.6 at baseline to 5.9 ± 3.2 at Week 4 in the elobixibat group ( P = 0.0079), but not in the placebo group (4.5 ± 2.7 to 5.3 ± 3.5; P = 0.0889). On analysis of covariance, the between‐group difference in frequency changes at Week 4 (primary endpoint) was not significant after adjustment by baseline and sex (point estimate = 0.8; 95% confidence interval = −0.57 to 2.09, P = 0.2601), although a significant difference ( P = 0.0011) was evidenced at Week 1 by a similar analysis. Stool form and scores of satisfaction and stigma were improved by elobixibat. Adverse events were as previously reported.

Conclusions

Elobixibat improved the SBM frequency, though the defined primary endpoint was not evidenced. QOL parameters (stool consistency and treatment satisfaction) were also improved. Elobixibat may have therapeutic benefits in PD patients suffering from chronic constipation. Trial Registration Information Trial Registration Number: JPRN‐jRCTs031200172 (submitted: October 26, 2020; first patient enrolment: December 23, 2020; https://jrct.niph.go.jp/en-latest-detail/jRCTs031200172 ).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DipeptidesGastrointestinal DiseasesParkinson DiseaseThiazepinesHumansChronic DiseaseConstipationQuality of LifeDouble-Blind Method

Stichwörter der Autor:innen

Parkinson's diseaseautonomicclinical neurologyconstipationmovement disordersrandomized trials

Substanzen

DipeptideselobixibatThiazepines

Autor:innen und Institutionen

  • Department of Neurology, Juntendo University Faculty of Medicine, Tokyo, Japan.
  • Department of Neurology, Juntendo Nerima Hospital, Tokyo, Japan.
  • Department of Neurology, Juntendo Urayasu Hospital, Urayasu, Japan.
  • Juntendo Clinical Research and Trial Center, Juntendo University Hospital, Tokyo, Japan.

ORCID-Profile: Taku Hatano, Genko Oyama, Noriko Nishikawa, Taiji Tsunemi, Takashi Ogawa, Kensuke Daida, Shinji Saiki, Hikaru Kamo, Atsuhiko Shindo

Förderung

  • Mochida Pharmaceutical Co., Ltd.
  • EA Pharma Co., Ltd.

Zitieren

APA

Hatano, T., Oyama, G., Shimo, Y., Ogaki, K., Nishikawa, N., Nakamura, R., Tsunemi, T., Ogawa, T., Eguchi, H., Daida, K., Kurita, N., Ueno, S. I., Fukae, J., Sako, W., Shiina, K., Nakajima, S., Oji, Y., Wakamori, R., Saiki, S., …, & Hattori, N. (2024). Efficacy and Safety of Elobixibat in Parkinson's Disease with Chronic Constipation: CONST‐PD Study. Movement Disorders Clinical Practice. https://doi.org/10.1002/mdc3.13972

Vancouver

Hatano T, Oyama G, Shimo Y, Ogaki K, Nishikawa N, Nakamura R, et al. Efficacy and Safety of Elobixibat in Parkinson's Disease with Chronic Constipation: CONST‐PD Study. Movement Disorders Clinical Practice. 2024. doi:10.1002/mdc3.13972

BibTeX
@article{Hatano2024,
  author = {Hatano, Taku and Oyama, Genko and Shimo, Yasushi and Ogaki, Kotaro and Nishikawa, Noriko and Nakamura, Ryota and Tsunemi, Taiji and Ogawa, Takashi and Eguchi, Hiroto and Daida, Kensuke and Kurita, Naohide and Ueno, Shin-Ichi and Fukae, Jiro and Sako, Wataru and Shiina, Kenta and Nakajima, Sho and Oji, Yutaka and Wakamori, Ryo and Saiki, Shinji and Nishioka, Kenya and Okuzumi, Ayami and Taniguchi, Daisuke and Takeshige-Amano, Haruka and Fuse, Atsuhito and Nakajima, Asuka and Kano, Masayoshi and Kamo, Hikaru and Yamashita, Yuri and Shindo, Atsuhiko and Yanagisawa, Naotake and Hattori, Nobutaka},
  title = {Efficacy and Safety of Elobixibat in Parkinson's Disease with Chronic Constipation: CONST‐PD Study},
  journal = {Movement Disorders Clinical Practice},
  year = {2024},
  doi = {10.1002/mdc3.13972}
}
Kostenlos starten →